Share this alert above (NEW YORK)–Rising India, Inc. (OTC:RSII), a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, sees investor interest rise on trial launch of cancer therapy drug Cannophen™.
One of the first products to draw attention of traders to RSII was their TSW product for muscle and joint pain, back pain, neuropathy/nerve pain and arthritis. TSW Pain, a topical pain relief cream for muscle and joint relief, is currently under testing to meet FDA requirements.
With the explosive epidemic of opioid addiction sweeping this country any alternative pain therapy away from these awful medications is sure to catch attention of investors, and TSW Pain is something to watch.
In addition to that the Company is also in testing phase with a Scar Peptide Serum to helps with scare and tissue repair.
But what really set RSII on fire in recent weeks was news that they will be partnering with PAO Group (OTC:PAOG) to offer a free trial of Cannophen™ to patients in the state of Ohio.
Cannophen™ is an oral capsule with laboratory controlled metered dosing that can be blended in exacting ratios of THC, CBD and strain specific terpenes. It is easily digestible and fast acting and designed for patients that do not want to smoke/vape or use off-tasting tinctures.
CBD Cancer Research
Mounting evidence shows ‘cannabinoids’ in marijuana slow cancer growth, inhibit formation of new blood cells that feed a tumor, and help manage pain, fatigue, nausea, and other side effects. According to The National Cancer Institute, Studies in mice and rats have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow.
Laboratory and animal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells. One notable study of delta-9-THC in hepatocellular carcinoma (liver cancer) cells showed that it damaged or killed the cancer cells. The same study of delta-9-THC in mouse models of liver cancer showed that it had antitumor effects. Delta-9-THC has been shown to cause these effects by acting on molecules that may also be found in non-small cell lung cancer cells and breast cancer cells.
There can be no doubt that RSII has caught the attention of traders to their stock, which closed Friday at around $0.02 per share. RSII has been one of the most discussed plays among traders in the past few trading sessions, and sure to say any additional news from the Company will be closely watched.
Register for Updates
Since RSII story is just beginning to unfold, Wall Street Newscast will be providing ongoing coverage on their anticipated roll-out of Cannophen, and investors interested in getting updates on this, or other alerts within the small cap sector can register to our free investor mailing list at